PE20141149A1 - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents
Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)Info
- Publication number
- PE20141149A1 PE20141149A1 PE2013002137A PE2013002137A PE20141149A1 PE 20141149 A1 PE20141149 A1 PE 20141149A1 PE 2013002137 A PE2013002137 A PE 2013002137A PE 2013002137 A PE2013002137 A PE 2013002137A PE 20141149 A1 PE20141149 A1 PE 20141149A1
- Authority
- PE
- Peru
- Prior art keywords
- tissue factor
- tfpi
- monoclonal antibodies
- antibodies against
- path inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471101P | 2011-04-01 | 2011-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141149A1 true PE20141149A1 (es) | 2014-08-28 |
Family
ID=46932389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002137A PE20141149A1 (es) | 2011-04-01 | 2012-03-30 | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) |
Country Status (37)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101792032B1 (ko) | 2008-12-19 | 2017-11-02 | 백스터 인터내셔널 인코포레이티드 | Ｔｆｐｉ 억제제 및 사용 방법 |
| WO2010072691A1 (en) † | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| PT3345615T (pt) | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| DK2547355T3 (en) | 2010-03-19 | 2017-03-20 | Baxalta GmbH | TFPI INHIBITORS AND METHODS OF USE |
| PL2694544T3 (pl) * | 2011-04-01 | 2019-07-31 | Bayer Healthcare Llc | Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI) |
| BR112014022435B1 (pt) | 2012-03-21 | 2023-02-14 | Takeda Pharmaceutical Company Limited | Inibidores de tfpi e métodos de uso |
| US9975962B2 (en) | 2012-03-30 | 2018-05-22 | Bayer Healthcare Llc | Thrombin/plasmin-regulated antibodies that bind TFPI |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US9896513B2 (en) * | 2013-03-15 | 2018-02-20 | Novo Nordisk A/S | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor |
| EP2970497B1 (en) | 2013-03-15 | 2017-10-25 | Bayer HealthCare LLC | Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics |
| EP3022228B1 (en) | 2013-07-19 | 2019-02-27 | Novo Nordisk A/S | Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| JP6783754B2 (ja) * | 2014-09-17 | 2020-11-11 | ノヴォ ノルディスク アー／エス | 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体 |
| MY178445A (en) * | 2015-02-25 | 2020-10-13 | Mogam Inst Biomedical Res | Novel antibody binding to tfpi and composition comprising the same |
| KR102438650B1 (ko) * | 2015-08-19 | 2022-08-31 | 화이자 인코포레이티드 | 조직 인자 경로 억제제 항체 및 그의 용도 |
| JP7444059B2 (ja) * | 2018-07-25 | 2024-03-06 | ソニーグループ株式会社 | 血液凝固系解析装置 |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06153985A (ja) * | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| WO2010072691A1 (en) * | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| PT3345615T (pt) * | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| PL2694544T3 (pl) * | 2011-04-01 | 2019-07-31 | Bayer Healthcare Llc | Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI) |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
-
2012
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
-
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039B1/en unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
-
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
-
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
-
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
-
2019
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
-
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
-
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141149A1 (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| CL2022000328A1 (es) | Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017) | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| MX2023004333A (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. | |
| AR080026A1 (es) | Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4) | |
| MX2018008658A (es) | Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna. | |
| UY34116A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
| PE20250415A1 (es) | Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| MX2017006323A (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| MY166776A (en) | Humanised anti-ctla4 antibodies | |
| CO6390041A2 (es) | Agentes y antagonistas fijaodres de notch y metodos para el uso de los mismos. | |
| CO6300826A2 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| AR079572A1 (es) | Anticuerpos que se enlazan a los epitopos de un polipeptido wise | |
| PE20141563A1 (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular | |
| PE20141548A1 (es) | Anticuerpo anti-alfabeta tcr | |
| CO6950477A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| AR084627A1 (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica | |
| PE20190171A1 (es) | Anticuerpos de union a trombina y usos del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |